acalabrutinib

Term ID

CHEBI:167707

Synonyms

(S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide
4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide
acalabrutinib
acalabrutinibum
ACP-196
Calquence

(all 7)

Definition

A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

References

(all 37)

Ontology

ChEBI ( EBI )

Relationships

is a type of: aromatic amine benzamides imidazopyrazine pyridines pyrrolidinecarboxamide ... Show All 8 Terms

aromatic amine benzamides imidazopyrazine pyridines pyrrolidinecarboxamide secondary carboxamide tertiary carboxamide ynone Show first 5 Terms
has_role: antineoplastic agent apoptosis inducer EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor

antineoplastic agent apoptosis inducer EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Show first 5 Terms

Phenotype

Phenotype resulting from acalabrutinib

Phenotype where environments contain acalabrutinib

Phenotype modified by environments containing acalabrutinib

Phenotype affecting acalabrutinib

Human Disease Model